Jamie is the Head of Commercial at Alderley Park, the UK’s largest single site bioscience campus, where he leads the commercial team leasing laboratory and office space to businesses in the lifescience, technology and innovation sectors. He is a chartered surveyor who has spent the last 11 years working in the North West office and lab markets. Prior to joining Alderley Park he worked at a multinational property consultancy advising landlords on leasing workspace on some of the region’s leading schemes and latterly for tenants, including FTSE 100 businesses, on their workspace acquisitions. Recently he was involved in the establishment of the Lighthouse Lab at Alderley Park.

Dr. Hawkins is a world-renowned medical oncologist and biotech innovator with a focus on the development of novel cell and gene therapies. Dr. Hawkins founded Immetacyte Ltd, a cell therapy company spun out of the University of Manchester, which became fully independent from the University in 2015 and developed the key technologies in Tumour Infiltrating Lymphocytes (TIL) which Instil is advancing. He became full time CEO of Immetacyte from 2018 until the acquisition by Instil Bio when he became Chief Strategy Advisor. Instil Bio has recently completed a series of private funding rounds and an IPO on NASDAQ raising over $340 M on listing. After Medical Training Bob undertook a PhD with Greg winter and Caesar Milstein at the Laboratory of Molecular Biology in Cambridge during which time, he developed the methods to select high-affinity antibodies used for the development of Humira®, and acted as a founding consultant of Cambridge Antibody Technology (acquired by AstraZeneca in 2006). Furthermore, Dr. Hawkins led the team that developed the first phage-derived single-chain antibody to be used in a clinical trial in the world. He subsequently focussed on cell and gene therapy from a laboratory research perspective and cancer immunotherapy clinically. He moved to the University of Manchester as Cancer Research UK Professor of Medical Oncology in 1998 and led the team that did the first CAR-T trials in the UK. He led the largest European scientific consortium in engineered T cell therapy (ATTACK) and subsequent training and clinical programs and was also a founding consultant to Oxford Biomedica. As a clinical investigator, Dr. Hawkins has been principal investigator on more than 20 clinical trials including several practice changing studies in kidney cancer. Dr. Hawkins has served on the scientific advisory boards of global biopharmaceutical companies and on national and international grants committees.

Eleanor Jukes is the Head of Transactions for the Urban Regeneration team within Legal & General Capital (LGC). She oversees investment activity across the portfolio, working closely with colleagues in LGIM Real Assets and Legal & General Retirement, and is a Board Director of the BruntWood SciTech JV. Eleanor joined LGC in 2019, having spent five years as the Senior Strategist within LGIM’s Real Assets team. Her responsibilities include developing themes for investment strategy, advising the fund management team on stock selection and sector positioning, and compiling market forecasts. She specialised in the alternative property sectors, focusing predominately on residential and healthcare property. Eleanor joined LGIM in 2014 from Schroders where she worked in the Real Estate Investment Management Team.